Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-naïve inci...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonneau, Gérald, Channick, Richard N., Delcroix, Marion, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Jansa, Pavel, Le Brun, Franck-Olivier, Mehta, Sanjay, Perchenet, Loic, Pulido, Tomás, Sastry, B.K.S., Sitbon, Olivier, Souza, Rogério, Torbicki, Adam, Rubin, Lewis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664609/
https://www.ncbi.nlm.nih.gov/pubmed/26493786
http://dx.doi.org/10.1183/13993003.00364-2015

Ejemplares similares

Ejemplares similares